Written and maintained by CASRAI Editorial Board
Last updated
The Child-Pugh score—formally the Child-Turcotte-Pugh (CTP) classification—is the foundational clinical and laboratory staging system used worldwide to assess the severity of chronic liver disease and cirrhosis, estimate surgical and variceal-bleeding mortality, and stratify hepatic drug-clearance cohorts in regulatory clinical pharmacology studies. Originally proposed in 1964 by surgeons Charles G. Child and Jeremiah G. Turcotte at the University of Michigan to predict mortality after portocaval shunt surgery, and modified in 1973 by R. N. H. Pugh and colleagues (who replaced subjective nutritional status with prothrombin time / International Normalized Ratio [INR] and assigned 1 to 3 points per parameter), the CTP score ranges from 5 to 15 points across three severity classes: Child-Pugh Class A (5–6 points), Class B (7–9 points), and Class C (10–15 points).
In hepatology clinical research, liver transplant allocation, and electronic clinical outcome assessment (eCOA) / HL7 FHIR Observation pipelines, the categorical Child-Pugh score operates alongside the continuous logarithmic Model for End-Stage Liver Disease (MELD, MELD-Na, and MELD 3.0), with each instrument serving distinct regulatory and clinical roles.
What Are the 5 Clinical and Laboratory Variables (Bilirubin, Albumin, INR, Ascites, Encephalopathy) in the Child-Turcotte-Pugh (CTP) Score (5–15 Points, Classes A, B, C)?
The Child-Turcotte-Pugh score sums 3 objective laboratory biomarkers (reflecting hepatic excretory clearance and synthetic capacity) and 2 clinician-assessed physical findings (reflecting portal hypertension and portosystemic shunting), each graded from 1 point (least severe) to 3 points (most severe):
| Clinical or Laboratory Parameter | 1 Point | 2 Points | 3 Points |
|---|---|---|---|
| 1. Total Serum Bilirubin (Non-cholestatic cirrhosis) (In Primary Biliary Cholangitis [PBC] or Primary Sclerosing Cholangitis [PSC]) |
< 2.0 mg/dL (< 34 µmol/L) (PBC/PSC: < 4.0 mg/dL) |
2.0 – 3.0 mg/dL (34 – 50 µmol/L) (PBC/PSC: 4.0 – 10.0 mg/dL) |
> 3.0 mg/dL (> 50 µmol/L) (PBC/PSC: > 10.0 mg/dL) |
| 2. Serum Albumin | > 3.5 g/dL (> 35 g/L) |
2.8 – 3.5 g/dL (28 – 35 g/L) |
< 2.8 g/dL (< 28 g/L) |
| 3. Prothrombin Time (PT) / INR | INR < 1.7 (or PT prolongation < 4 sec) |
INR 1.7 – 2.3 (or PT prolongation 4 – 6 sec) |
INR > 2.3 (or PT prolongation > 6 sec) |
| 4. Ascites | None | Mild / Slight (or easily controlled with diuretics) |
Moderate to Severe (or refractory / poorly controlled despite diuretics) |
| 5. Hepatic Encephalopathy (West Haven Criteria) |
None | Grade I – II (mild confusion, asterixis, or medically controlled with lactulose/rifaximin) |
Grade III – IV (somnolence, stupor, coma, or refractory encephalopathy) |
Child-Pugh Classes (A, B, and C): Clinical Interpretation and Prognosis
- Child-Pugh Class A (5 to 6 points — Well-Compensated Cirrhosis / Mild Hepatic Impairment): Historical 1-year survival approaches 100% and 2-year survival is approximately 85%. Patients are generally candidates for elective non-hepatic surgery and standard systemic oncology regimens (such as first-line hepatocellular carcinoma [HCC] systemic trials, which typically restrict enrollment to Child-Pugh Class A).
- Child-Pugh Class B (7 to 9 points — Significant Functional Compromise / Moderate Hepatic Impairment): Historical 1-year survival is approximately 80% and 2-year survival is approximately 60%. Marks the clinical transition to decompensated cirrhosis; requires dose adjustments for hepatically metabolized drugs and carries elevated perioperative morbidity (~30% mortality in major abdominal surgery).
- Child-Pugh Class C (10 to 15 points — Decompensated Cirrhosis / Severe Hepatic Impairment): Historical 1-year survival is approximately 45% and 2-year survival is approximately 35%. Elective non-transplant surgery is generally contraindicated (perioperative mortality 70%–80%), and patients require urgent evaluation for liver transplantation or palliative care.
How Did MELD Evolve from Original MELD to MELD-Na and MELD 3.0 (Kim et al., Adding Female Sex and Serum Albumin with Creatinine Cap at 3.0 mg/dL)?
While the Child-Pugh score remains the standard for drug-dosing studies, its reliance on two subjective clinical variables (ascites and encephalopathy), ceiling effects (a bilirubin of 4 mg/dL and 40 mg/dL both receive 3 points), and coarse 3-tier grouping made it unsuitable for prioritizing organ allocation on the national liver transplant waiting list. To provide a continuous, purely objective predictor of 90-day mortality in cirrhosis, Malinchoc et al. (2000) and Kamath et al. (2001) at the Mayo Clinic developed the Model for End-Stage Liver Disease (MELD), which has evolved through three generations in Organ Procurement and Transplantation Network (OPTN) / UNOS policy:
| Model Generation | Primary Citation & OPTN Adoption | Mathematical Formula & Variable Bounds |
|---|---|---|
| 1. Original MELD (MELDi) | Kamath et al. (2001); OPTN adoption Feb 2002 |
MELDi = 9.57 × ln(Creatinine) + 3.78 × ln(Bilirubin) + 11.20 × ln(INR) + 6.43(Multiplied by 10 and rounded to nearest integer; range 6–40. Minimum value for Bilirubin, INR, and Creatinine set to 1.0; Creatinine capped at 4.0 mg/dL or set to 4.0 if ≥2 dialysis treatments or 24h CVVHD in prior week.) |
| 2. MELD-Na | Kim et al. (2008); OPTN adoption Jan 2016 |
For patients with MELDi > 11:MELD-Na = MELDi + 1.32 × (137 − Na) − [0.033 × MELDi × (137 − Na)](Serum Sodium [Na] bounded between 125 mEq/L and 137 mEq/L to capture the independent mortality risk of portal-hypertensive dilutional hyponatremia.) |
| 3. MELD 3.0 | W. Ray Kim et al. (2021); OPTN adoption July 2023 |
MELD 3.0 = 1.33 × (Female) + 4.56 × ln(Bilirubin) + 0.82 × (137 − Na) − 0.24 × (137 − Na) × ln(Bilirubin) + 9.09 × ln(INR) + 11.14 × ln(Creatinine) + 1.85 × (3.5 − Albumin) − 1.83 × (3.5 − Albumin) × ln(Creatinine) + 6(Rounded to nearest integer; range 6–40.) |
Why MELD 3.0 Was Introduced (Kim et al., Gastroenterology 2021): Under MELD-Na, women experienced significantly higher waiting-list mortality and lower transplant rates than men because women have lower baseline muscle mass (generating lower serum creatinine for the same true glomerular filtration rate [GFR]) and smaller abdominal cavities. MELD 3.0 corrected this disparity and improved 90-day mortality discrimination (C-statistic 0.869) through four structural updates:
- Addition of Female Sex (+1.33 points): Directly compensates for sex-based differences in serum creatinine relative to true renal function.
- Lowering the Serum Creatinine Upper Cap from 4.0 mg/dL to 3.0 mg/dL: Prevents artificial inflation of creatinine weight in patients with high muscle mass or chronic kidney disease, and sets creatinine to 3.0 mg/dL for patients on renal replacement therapy.
- Addition of Serum Albumin (bounded between 1.5 g/dL and 3.5 g/dL): Re-introduces hepatic synthetic and nutritional reserve into the survival equation.
- Two Interaction Terms: Models the attenuating interaction between Bilirubin and Sodium (
−0.24 × [137 − Na] × ln[Bilirubin]) and between Creatinine and Albumin (−1.83 × [3.5 − Albumin] × ln[Creatinine]).
How Does FDA Guidance on Pharmacokinetics in Patients with Impaired Hepatic Function Use Child-Pugh Classes A, B, and C for Dosing Studies?
In the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function — Study Design, Data Analysis, and Impact on Dosing and Labeling (as well as European Medicines Agency [EMA] hepatic impairment guidelines), the Child-Turcotte-Pugh classification—not MELD—is the mandated regulatory framework for categorizing hepatic impairment in Phase I pharmacokinetic (PK) bridging trials:
- When a Dedicated Hepatic PK Study Is Required: Sponsors must conduct a hepatic impairment PK study when hepatic metabolism and/or biliary excretion accounts for more than 20% of the absorbed drug’s elimination, or when the drug has a narrow therapeutic index.
- Full Study Design (All 3 Child-Pugh Classes + Matched Controls): Enrolls parallel cohorts across Mild Hepatic Impairment (Child-Pugh Class A, 5–6 points), Moderate Hepatic Impairment (Child-Pugh Class B, 7–9 points), and Severe Hepatic Impairment (Child-Pugh Class C, 10–15 points) alongside healthy matched controls (matched for age, sex, and body weight), typically with at least 6–8 evaluable subjects per group, measuring both total and unbound (free) plasma drug concentrations (critical because hypoalbuminemia in Child-Pugh B/C alters protein binding).
- Reduced (Staged) Study Design: The FDA permits sponsors to initially conduct a reduced PK study comparing only Moderate Hepatic Impairment (Child-Pugh Class B) against healthy controls; if no clinically meaningful increase in unbound area under the curve (AUC) or Cmax is observed in Class B, no dose adjustment is needed for Class A or B, whereas significant PK divergence triggers evaluation of Class A and/or contraindicating language for Class C in Section 8.7 (Hepatic Impairment) of the FDA Prescribing Information.
- Trial Eligibility & ePRO/COA Capture: In pivotal Phase II/III oncology and hepatology trials, Child-Pugh score and ePRO in clinical trials / patient-reported outcome measures (PROMs) are captured at screening to ensure patients with decompensated Child-Pugh B/C cirrhosis are not exposed to hepatotoxic systemic doses calibrated only for Child-Pugh A physiology.
Frequently Asked Questions
What are the 5 clinical and laboratory variables (bilirubin, albumin, INR, ascites, encephalopathy) in the Child-Turcotte-Pugh (CTP) score (5–15 points, Classes A, B, C)?
The Child-Turcotte-Pugh (CTP) score evaluates 5 variables—total serum bilirubin (<2, 2–3, >3 mg/dL), serum albumin (>3.5, 2.8–3.5, <2.8 g/dL), INR (<1.7, 1.7–2.3, >2.3), ascites (none, mild/diuretic-controlled, moderate-to-severe/refractory), and hepatic encephalopathy (none, Grade I–II, Grade III–IV)—assigning 1 to 3 points each for a total of 5 to 15 points: Class A (5–6 points, well-compensated), Class B (7–9 points, moderate compromise), and Class C (10–15 points, decompensated cirrhosis).
How did MELD evolve from original MELD to MELD-Na and MELD 3.0 (Kim et al., adding female sex and serum albumin with creatinine cap at 3.0 mg/dL)?
Original MELD (2001/2002) predicted 90-day liver transplant waitlist mortality from log-transformed bilirubin, INR, and creatinine (capped at 4.0 mg/dL). MELD-Na (2008/2016) added serum sodium (bounded at 125–137 mEq/L). MELD 3.0 (Kim et al., 2021; adopted by OPTN in July 2023) added 1.33 points for female sex, incorporated serum albumin (bounded at 1.5–3.5 g/dL), lowered the serum creatinine upper cap from 4.0 to 3.0 mg/dL, and added bilirubin-sodium and creatinine-albumin interaction terms.
How does FDA Guidance on Pharmacokinetics in Patients with Impaired Hepatic Function use Child-Pugh Classes A, B, and C for dosing studies?
FDA Guidance uses the Child-Pugh score to stratify Phase I hepatic pharmacokinetic (PK) bridging studies into Mild (Child-Pugh Class A, 5–6 points), Moderate (Class B, 7–9 points), and Severe (Class C, 10–15 points) hepatic impairment cohorts compared against healthy matched controls, measuring both total and unbound drug exposure (AUC and Cmax) to establish dose reductions or contraindications in Section 8.7 of the FDA drug label.
